Search Within

Aaron David Goldberg

Formats
  1. Meeting Abstract (61)
  2. Journal Article (30)
  3. Research Letter (6)
  4. Correspondence (3)
  5. Editorial (3)
  6. Review (2)
  7. Book Section (1)
Groups
  1. Adult Leukemia (106)
  2. Center for Hematologic Malignancies (106)
  3. Department of Medicine (106)
  4. Hematologic Malignancies, Division of (106)
  5. Weinberg Fellows (106)
  6. Hematology-Oncology Fellows (48)

More Groups

People
  1. Martin Tallman (46)
  2. Eytan Stein (38)
  3. Christopher Famulare (36)
  4. Ross Levine (20)
  5. Jan Bewersdorf (19)
  6. Andriy Derkach (18)

More People

Years
  1. 2025 (2)
  2. 2024 (11)
  3. 2023 (20)
  4. 2022 (15)
  5. 2021 (15)
  6. 2020 (15)

More Years

Publications
  1. Blood (55)
  2. Leukemia and Lymphoma (8)
  3. American Journal of Hematology (6)
  4. Blood Advances (5)
  5. Journal of Clinical Oncology (5)
  6. Haematologica (4)

More Publications

Publishers
  1. American Society of Hematology (60)
  2. Taylor & Francis Group (8)
  3. American Society of Clinical Oncology (6)
  4. John Wiley & Sons, Inc. (5)
  5. Ferrata Storti Foundation (4)
  6. Nature Publishing Group (4)

More Publishers

Results (106)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Venetoclax–azacitidine versus azacitidine for the treatment of primary refractory or first relapsed acute myeloid leukemia. An IPC-DATAML-MSKCC retrospective study
    Correspondence

    Petit, C.; Higue, J.; Acheaibi, Z.; Gilhodes, J.; Hospital, M. A.; Devillier, R.; Bewersdorf, J.; Goldberg, A. D.; Pigneux, A.; Vey, N.; more...
    American Journal of Hematology (2025)

    Fulltext@MSK | Save
  • HMA/VEN treatment modifications and associated outcomes in IDH-mutant AML
    Journal Article

    Chin, K. K.; Derkach, A.; Famulare, C.; Gupta, G. K.; Borge, P. D.; Geyer, M.; Goldberg, A. D.; Haque, T.; Park, J. H.; Roeker, L. E.; more...
    Leukemia and Lymphoma (2025)

    Fulltext@MSK | Save
  • The prognostic and predictive value of RUNX1 mutations in newly diagnosed acute myeloid leukemia - An international multicenter cohort study
    Meeting Abstract

    Bystrom, R. P.; Bewersdorf, J. P.; Liu, Y.; Schaefer, E. J.; Shallis, R. M.; Boussi, L.; Zucenka, A.; Garciaz, S.; Aguirre, L. E.; DeAngelo, D. J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Outcomes with HMA plus venetoclax vs intensive chemotherapy in AML patients with chromosome 5 and 7 abnormalities
    Meeting Abstract

    Boussi, L.; Bewersdorf, J. P.; Liu, Y.; Shallis, R. M.; Aguirre, L. E.; Zucenka, A.; Garciaz, S.; Bystrom, R. P.; DeAngelo, D. J.; Stone, R. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Comparative analysis of outcomes with HMA plus venetoclax vs intensive chemotherapy in AML patients harboring very-high risk cytogenetics
    Meeting Abstract

    Aguirre, L. E.; Bewersdorf, J. P.; Liu, Y.; Shallis, R. M.; Boussi, L.; Zucenka, A.; Garciaz, S.; Bystrom, R. P.; Deangelo, D. J.; Stone, R. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Leukemiaphysician's perspective on transplant in patients with TP53 mutated acute myeloid leukemia
    Meeting Abstract

    Vanegas, Y. A. M.; El Khatib, S. Y. M.; Hisrich, B.; Coltoff, A.; Shallis, R. M.; Patel, A. A.; Bewersdorf, J. P.; Oh, T. S.; Abaza, Y.; Foucar, C.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Prognostic impact of 'multi-hit' versus 'single-hit' TP53 alteration in patients with acute myeloid leukemia: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases
    Journal Article

    Badar, T.; Nanaa, A.; Atallah, E.; Shallis, R. M.; Craver, E. C.; Li, Z.; Goldberg, A. D.; Saliba, A. N.; Patel, A.; Bewersdorf, J. P.; more...
    Haematologica (2024)

    Fulltext@MSK | Save
  • TP53 Y220C mutations in patients with myeloid malignancies
    Research Letter

    Gener-Ricos, G.; Bewersdorf, J. P.; Loghavi, S.; Bataller, A.; Goldberg, A. D.; Sasaki, K.; Famulare, C.; Takahashi, K.; Issa, G. C.; Borthakur, G.; more...
    Leukemia and Lymphoma (2024)

    Fulltext@MSK | Save
  • Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML
    Journal Article

    Bewersdorf, J. P.; Shimony, S.; Shallis, R. M.; Liu, Y.; Berton, G.; Schaefer, E. J.; Zeidan, A. M.; Goldberg, A. D.; Stein, E. M.; Marcucci, G.; more...
    Blood Advances (2024)

    Fulltext@MSK | Save
  • Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia—A multicenter cohort study
    Correspondence

    Bewersdorf, J. P.; Shimony, S.; Shallis, R. M.; Liu, Y.; Berton, G.; Schaefer, E. J.; Zeidan, A. M.; Goldberg, A.; Stein, E.; Marcucci, G.; more...
    American Journal of Hematology (2024)

    Fulltext@MSK | Save